Response to 'Resistin letters'
Kidney International (2006) 70, 1372. doi:10.1038/sj.ki. 5001602 We thank Fagerberg et al. for their contribution to the growing body of evidence refuting a causative relationship between the protein resistin and insulin resistance in man.
1 Indeed, resistin was first described as found in inflammatory zone (FIZZ)-1, indicating its structural similarity to several other proinflammatory cytokines. Indeed, resistin is expressed mainly in immunocompetent cells such as leukocytes, and not in adipocytes as had previously been thought.
3,4
Given the fact that even a mild renal function impairment is associated with a chronic low-grade inflammation 5 and a markedly increased risk of cardiovascular death, it is not surprising that the patients in the study of Fagerberg et al. displayed increased resistin levels that were also correlated with serum creatinine, C-reactive protein, and leukocyte counts.
Taken together, we believe that this study further underscores the relationship between decreasing renal function and increased risks of inflammation and cardiovascular disease. Resistin is one part of this complex, where we are still looking for a unifying mechanism and an effective therapy.
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